 |
| |
|
·¹º¸ÆÄÆ®Á¤5mg(¿Ã·ÎÆÄŸµò¿°»ê¿°) Levopat Tab. 5mg
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
649000050[A34851001]
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2025.09.01)(ÇöÀç¾à°¡)
\130 ¿ø/1Á¤(2023.09.05)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
´ãȲÀû»öÀÇ ¿øÇü Çʸ§ÄÚÆÃÁ¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
30Á¤/º´, 300Á¤/º´ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 5¹Ð¸®±×·¥ |
300 Á¤ |
º´ |
8806490000504 |
8806490000528 |
|
| 5¹Ð¸®±×·¥ |
30 Á¤ |
º´ |
8806490000504 |
8806490000511 |
|
|
| ÁÖ¼ººÐÄÚµå |
391703ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
⦁¼ºÀÎ : ¾Ë·¹¸£±âºñ¿°, ´ã¸¶Áø, ÇǺÎÁúȯ(½ÀÁø・ÇǺο°, ¾çÁø, ÇǺμҾçÁõ, ½É»ó¼º°Ç¼±)¿¡ µû¸¥ °¡·Á¿òÁõ
⦁¼Ò¾Æ : ¾Ë·¹¸£±âºñ¿°, ´ã¸¶Áø, ÇǺÎÁúȯ(½ÀÁø・ÇǺο°, ÇǺμҾçÁõ)¿¡ µû¸¥ °¡·Á¿òÁõ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
⦁¼ºÀÎ : º¸Åë ¼ºÀο¡°Ô´Â 1ȸ ¿Ã·ÎÆÄŸµò ¿°»ê¿°À¸·Î¼ 5mgÀ» 1ÀÏ 2ȸ(¾ÆÄ§ ¹× ÃëħÀü) °æ±¸ Åõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
⦁10¼¼ ÀÌ»óÀÇ ¼Ò¾Æ : 1ȸ ¿Ã·ÎÆÄŸµò ¿°»ê¿°À¸·Î¼ 5mg 1 ÀÏ 2 ȸ(¾ÆÄ§ ¹× ÃëħÀü) °æ±¸ Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾àÀº À¯´çÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î, °¥¶ôÅä¿À½º ºÒ³»¼º(galactose intolerance), Lapp À¯´çºÐÇØÈ¿¼Ò °áÇÌÁõ(Lapp lactose deficiency) ¶Ç´Â Æ÷µµ´ç-°¥¶ôÅä¿À½º Èí¼öÀå¾Ö(glucose-galactose malabsorption) µîÀÇ À¯ÀüÀûÀÎ ¹®Á¦°¡ Àִ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏ¸é ¾È µÈ´Ù. (À¯´çÇÔÀ¯Á¦Á¦ ÇÑÇÔ)
|
| ½ÅÁßÅõ¿© |
1) ½Å±â´É ÀúÇÏ È¯ÀÚ (³ôÀº Ç÷Áß³óµµ°¡ Áö¼ÓµÉ ¿ì·Á°¡ ÀÖ´Ù)
2) °í·ÉÀÚ
3) °£±â´ÉÀåÇØ°¡ Àִ ȯÀÚ (°£±â´ÉÀåÇØ°¡ ¾Ç鵃 ¿ì·Á°¡ ÀÖ´Ù)
4) ÀÌ ¾àÀº Ȳ»ö5È£(¼±¼Â¿»·Î¿ì FCF, Sunset Yellow FCF)¸¦ ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. (Ȳ»ö5È£ ÇÔÀ¯Á¦Á¦ ÇÑÇÔ)
|
| ÀÌ»ó¹ÝÀÀ |
<¼ºÀÎ>
1) ÁÖ¿ä ÀÌ»ó¹ÝÀÀÀ¸·Î Á¹À½, ALT »ó½Â, ±Çۨ, AST »ó½Â, ±¸°¥, º¹Åë µîÀÌ ³ªÅ¸³µ´Ù.
2) Áß´ëÇÑ ÀÌ»ó¹ÝÀÀ
¨ç Àü°Ý¼º °£¿°, °£±â´É Àå¾Ö, Ȳ´Þ(ºóµµ ºÒ¸í): Àü°Ý¼º °£¿°, AST(GOT), ALT(GPT), ¥ã-GTP, LDH, Al-P µîÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·Î ÀÎÇÑ °£±â´É ÀÌ»ó°ú Ȳ´ÞÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù. µû¶ó¼ ȯÀÚµéÀ» ÁÖÀÇ ±í°Ô °üÂûÇϰí ÀÌ»óÀÌ ¹ß°ßµÇ¸é, Ä¡·á¸¦ Áß´ÜÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇàÇÑ´Ù.
3) ±âŸ ÀÌ»ó¹ÝÀÀ
¾Æ·¡¿Í °°Àº ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î, °üÂûÀ» ÃæºÐÈ÷ Çϰí, ÀÌ»óÀÌ ÀÎÁ¤µÈ °æ¿ì¿¡´Â °¨·®, ÈÞ¾à µîÀÇ ÀûÀýÇÑ Ã³Ä¡¸¦ ÇàÇÑ´Ù.
|
|
5% ÀÌ»ó
|
0.1% ÀÌ»ó,
5% ¹Ì¸¸
|
0.1% ¹Ì¸¸
|
ºóµµºÒ¸í
|
|
°ú¹ÎÁõ
|
|
È«¹Ý µîÀÇ ¹ßÁø, ºÎÁ¾(¾È¸é, »çÁö µî)
|
¼Ò¾ç, È£Èí°ï¶õ
|
|
|
Á¤½Å½Å°æ°è
|
Á¹À½
|
±Çۨ, ±¸°¥, µÎÅë, µÎÁß°¨, Çö±âÁõ
|
¸¶ºñ°¨, ÁýÁß·ÂÀúÇÏ
|
ºÒ¼öÀÇ ¿îµ¿(¾È¸é, »çÁö µî)
|
|
¼Òȱâ°è
|
|
º¹Åë, º¹ºÎºÒÄè°¨, ¼³»ç, ±¸¿ª
|
º¯ºñ, ±¸³»¿°, ±¸°¢¿°, ¼³Åë, °¡½¿¾ÎÀÌ, ½Ä¿åÁõ°¡
|
±¸Åä
|
|
°£Àå
|
|
°£±â´É ÀÌ»ó(AST(GOT), ALT(GPT), ¥ã-GTP, LDH, Al-P, ÃѺô¸®·çºó »ó½Â)
|
|
|
|
Ç÷¾×
|
|
¹éÇ÷±¸ Áõ°¡, ¹éÇ÷±¸ °¨¼Ò,
È£»ê±¸ Áõ°¡, ¸²ÇÁ±¸ °¨¼Ò
|
|
|
|
½ÅÀå,
ºñ´¢±â°è
|
|
´¢ÀáÇ÷,
BUN »ó½Â
|
´¢´Ü¹é ¾ç¼º,Ç÷ÁßÅ©·¹¾ÆÆ¼´Ñ »ó½Â, ¹è´¢°ï¶õ, ºó´¢Áõ
|
|
|
½ÉÇ÷°ü°è
|
|
|
½É°èÇ×Áø, Ç÷¾Ð »ó½Â
|
|
|
±âŸ
|
|
Ç÷ûÄÝ·¹½ºÅ×·Ñ »ó½Â
|
´¢´ç ¾ç¼º, ÈäºÎºÒÄè°¨, ¹Ì°¢ ÀÌ»ó, üÁß Áõ°¡, È«Á¶
|
¿ù°æÀÌ»ó, ±ÙÀ°Åë, °üÀýÅë
|
4) ±¹³» ½ÃÆÇ ÈÄ Á¶»ç °á°ú
±¹³»¿¡¼ Àç½É»ç¸¦ À§ÇÏ¿© 6³â µ¿¾È 1,542¸íÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ ½ÃÆÇ ÈÄ Á¶»ç°á°ú, ÀÌ»ó¹ÝÀÀ ¹ßÇöÀ²Àº Àΰú°ü°è¿Í »ó°ü¾øÀÌ ¾ÈÀü¼º Æò°¡´ë»óÀÚ 1,517·Ê Áß 22·Ê(1.5%, 95%½Å·Ú±¸°£: 0.85~2.05%)·Î º¸°íµÇ¾ú°í Á¶»çµÈ À¯ÇØ»ç·Ê ¹ßÇö°Ç¼ö´Â 26°ÇÀ̾úÀ¸¸ç, ÀÌ Áß ÀÌ ¾à°úÀÇ Àΰú°ü°è¸¦ ¹èÁ¦ÇÒ ¼ö ¾ø´Â °ÍÀ¸·Î Á¶»çµÈ °ÍÀº 1.4%(21·Ê/1,517·Ê, 22°Ç)ÀÌ´Ù. Á¶»çµÈ ÀÌ»ó¹ÝÀÀÀº ¾à¹°°úÀÇ Àΰú°ü°è¿¡ »ó°ü¾øÀÌ Á¹À½ÀÌ 1.1%(17·Ê/1517·Ê)·Î °¡Àå ¸¹¾ÒÀ¸¸ç º¹ºÎºÒÄè°¨ 0.2%(3·Ê/1,517·Ê), ¼Ó¾²¸² 0.06%(1·Ê/1,517·Ê), µþ²ÚÁú 0.06%(1·Ê/1,517·Ê), µÎÅë 0.1%(2·Ê/1,517·Ê), Àεο° 0.1%(2·Ê/1,517·Ê)ÀÇ ¹ßÇöÀ²·Î º¸°íµÇ¾ú½À´Ï´Ù. ¿¹ÃøÇÏÁö ¸øÇÑ ÀÌ»ó¹ÝÀÀÀ¸·Î ¼Ó¾²¸² 1°Ç, µþ²ÚÁú 1°Ç, Àεο° 2°ÇÀÌ º¸°íµÇ¾úÀ¸¸ç ÀÌ Áß ¾à¹°°úÀÇ Àΰú°ü°è¸¦ ¹èÁ¦ÇÒ ¼ö ¾ø´Â °ÍÀº µþ²ÚÁúÀ̾ú´Ù.
<¼Ò¾Æ>
ÀϺ»¿¡¼ ¼Ò¾Æ¸¦ ´ë»óÀ¸·Î ½Ç½ÃÇÑ 4°ÇÀÇ ÀÓ»ó ½ÃÇè¿¡¼ ÀÌ ¾àÀ» Åõ¿© ¹ÞÀº 417¸í Áß 62¸í(14.9%)¿¡¼ 78°ÇÀÇ ÀÌ»ó¹ÝÀÀÀÌ º¸°íµÇ¾ú´Ù.
ÁÖ¿ä ÀÌ»ó¹ÝÀÀÀº Á¹À½ 22°Ç(5.3%), ALT(GPT) »ó½Â 18°Ç(4.3%), AST(GOT) »ó½Â 8°Ç(1.9%), ¹éÇ÷±¸ Áõ°¡ 7°Ç(1.7%), ¥ã-GTP »ó½Â 3°Ç(0.7%) µîÀ̾ú´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
649000050[A34851001]
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2025.09.01)(Ãֽžడ)
\130 ¿ø/1Á¤(2023.09.05)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
´ãȲÀû»öÀÇ ¿øÇü Çʸ§ÄÚÆÃÁ¤Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| ´ëü°ü·Ã |
»ýµ¿¼º ½ÃÇè ¿Ï·á |
´ëüÁ¶Á¦ Àμ¾Æ¼ºê ǰ¸ñ |
¾÷µ¥ÀÌÆ®±âÁØÀÏ:2009.03.15 [´ëüÁ¶Á¦ Àμ¾Æ¼ºê Áö±Þ´ë»ó ǰ¸ñÀÔ´Ï´Ù/Àû¿ëÀÏ:20081101/½Ä¾àû°ø°í5384¹ø] |
| Æ÷À塤À¯Åë´ÜÀ§ |
30Á¤/º´, 300Á¤/º´ |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â, ½Ç¿Â(1~30¡É)º¸°ü |
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Olopatadine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Olopatadine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.
|
| Pharmacology |
Olopatadine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
|
| Half-life |
Olopatadine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 3 hours
|
| Absorption |
Olopatadine¿¡ ´ëÇÑ Absorption Á¤º¸ Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.
|
| Pharmacokinetics |
OlopatadineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£: ¾Ë·¯Áö¼º °á¸·¿°, ±¹¼ÒÁ¡¾ÈÁ¦- 30ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£: ¾Ë·¯Áö¼º °á¸·¿°, ±¹¼ÒÁ¡¾ÈÁ¦- 8½Ã°£
- ÃÖ°íÈ¿°ú ¹ßÇö½Ã°£: ±¹¼ÒÁ¡¾ÈÁ¦- 2½Ã°£ À̳»
- Èí¼ö:
1)±¹¼ÒÁ¡¾ÈÁ¦ – ¼Ò·® (0.15%ÀÇ olopatadine ophthalmic solutionÀ» 12½Ã°£¸¶´Ù 2ÁÖ°£ Åõ¿©½Ã Ç÷Áß ¾à¹°³óµµ´Â 0.5 ng/mL
- ´Ü¹é°áÇÕ: »ç¶÷¿¡°Ô¼´Â °üÂûµÇÁö ¾Ê¾ÒÀ½. (½ÇÇèÀûÀ¸·Î ·§Æ®¿¡¼´Â ¾à 44%)
- ´ë»ç:
1)±¹¼ÒÁ¡¾ÈÁ¦ - Mono-desmethyl metabolite(ºñȰ¼ºÇü)¿Í N-oxide derivative(ºñȰ¼ºÇü)À¸·Î ´ë»ç
- ¼Ò½Ç:
1)±¹¼ÒÁ¡¾ÈÁ¦ – ¹Ìº¯Èü·Î¼ ½Å¹è¼³ 60-70%ÀÓ.
2)°æ±¸Á¦ – 5mgÀ» 1ȸ °æ±¸Åõ¿©½Ã, 48½Ã°£³»¿¡ ¹Ì´ë»çü·Î 68%°¡ ´¢·Î ¹è¼³.
- À¯Áó¹è¼³: ·§Æ®¿¡°Ô °æ±¸Åõ¿©½Ã À¯ÁóºÐºñ°¡ °üÂûµÊ. ±×·¯³ª ±¹¼Ò¿ëÁ¦°¡ »ç¶÷ À¯ÁóÀ¸·Î ¹è¼³µÇÁö´Â ¾Ë·ÁÁ®ÀÖÁö ¾ÊÀ½.
- ¹Ý°¨±â: Á¡¾ÈÁ¦-3½Ã°£, °æ±¸Á¦- ¾à 8.75½Ã°£
|
| Biotransformation |
Olopatadine¿¡ ´ëÇÑ Biotransformation Á¤º¸ The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Olopatadine¿¡ ´ëÇÑ Description Á¤º¸ Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
|
| Drug Category |
Olopatadine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Allergic AgentsAnti-Inflammatory Agents, Non-SteroidalAntihistaminesHistamine H1 AntagonistsHistamine H1 Antagonists, Non-Sedating
|
| Smiles String Canonical |
Olopatadine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
|
| Smiles String Isomeric |
Olopatadine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
|
| InChI Identifier |
Olopatadine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-/f/h23H
|
| Chemical IUPAC Name |
Olopatadine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[(11Z)-11-(3-dimethylaminopropylidene)-6H-benzo[c][2]benzoxepin-2-yl]acetic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-08-28
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. OLOPATADINE[GGT Increase][Composite Activity](Score) I(Marginal) 0(Active) 0[Alkaline Phosphatase Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGOT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGPT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[LDH Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[GGT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|